

SUBJECT INDEX VOLUME 21

A

Accumbens, 694
 Acetazolamide, 368
 Activity, 731
 ADHD, 3
 Adolescents, 723
 -Adrenergic, 495
 Adrenergic- α_2 -Agonist-pharmacology, 495
 β -Adrenergic receptor, 147
 Adrenocorticotropin, 485
 Adults, 723
 Affective disorders, 408, 519
 Aggression, 755, 52S
 α -2 Agonists, 611
 Alcohol, 435
 Alcoholism, 51
 Alpha-2 adrenoceptor, 601
 Alzheimer's disease, S203
 Amnesia, 285
 AMPA, 211, 341
 Amphetamine, 550
 Amygdala, 93, 229, 507, 513, 52S, 68S
 Analgesia, 731
 Anger, 147
 Anhedonia, 247
 Animal models, S211, S158
 Anorexia nervosa, 503
 Antidepressant, 268, 91S
 Antidepressant therapy, 530
 Antidepressant treatment, 99S
 Antidepressants, 352, 745
 Antipsychotic, 622, S170
 Antipsychotic drugs, 101
 Antipsychotics, 93, S122
 Antisocial personality disorder, 51
 Anxiety, 147, 312, 485, 507, 513, 52S, 68S
 Apomorphine, 28
 Assessment tools, S203
 Association, 3
 Atrophy, 82
 Attention, S143
 Attention-drug-effects, 495
 Auditory cortex, 710
 Auditory evoked potentials, 710
 Autoradiography, S181

B

BDNF, 679
 Behavior, 679
 Behavioral sensitization, 550
 Benzodiazepine receptor, 513
 Benzodiazepines, 312
 Biological marker, 408
 Bipolar disorder, 63, 229, 474
 Bipolar illness, 717
 Blood flow velocity, 110
 Blood pressure, 755
 Brain, 99S
 Brain pathology, S203
 Bursting, 127

C

Ca^{2+} Channels, 161
 Calcification, 765
 Calcium, 775
 Cannabinoids, 773
 Catalepsy, 670
 Catecholamines, 40
 Cats, 9S
 Caudate, 694
 Caudate, frontal-subcortical circuits, 683
 Cerebellum, 63
 Cerebral cortex, 16S
 Cerebral glucose metabolism, 683
 Cerebral metabolic rates, 633
 Cerebral spinal fluid, 717
 Cerebral-ventricle, 82
 Cerebrospinal fluid, 99S
 Cerebrovascular circulation, 368
 Cerebrovascular resistance, 110
 Cholecystokinin, 485
 Cholinergic, 723
 Cigarette smoking, 195
 Cingulate, 633
 Cingulate cortex, 229
 Circadian rhythm, 352, 408
 Circadian timing system, 765
 Clonidine, 601
 Clonidine-pharmacology, 495
 Clozapine, 93, 211
 Co-localization, 33S
 Cocaine, 127, 294, 445, 575, 662
 Cocaine abuse, 110
 Cognition, S170
 Cognitive deficits, S170
 Cognitive function, S143
 Cognitive impairment, S203
 Cognitive side effects, 285
 Conditioning, 670
 Conduct disorder, 51
 Conflict, 507
 Consolidation, 731
 Constitutive activity, 61S
 Corticosteroid, 474
 Corticosterone, 399
 Corticotropin, 40
 Cortisol, 40, 474, 485
 Crack, 445
 CSF, 503
 Cued platform, 414
 Cytochrome oxidase, 229
 Cytochrome-c oxidase, 372

D

D₁ and D₂ dopamine receptors mRNA, 662
 D₃ dopamine receptor, 304
 D₂ receptor, 127, S181
 D₁Receptors, 641
 D-amphetamine, 380
 D-cycloserine, 203
 Dendrites, 161
 Dendritic compartment, 68S
 Dentate gyrus, 46S

Deoxyglucose, 427, 633, 773
 Depression, 69, 147, 247, 258, 268, 391, 474, 513, 52S, 99S
 Development, 723
 Dialysis, 268
 Dim-light, 408
 Dizocilpine, 119
 Dopamine, 17, 127, 161, 399, 560, 641, 694
 Dopamine antagonist, 575
 Dopamine D₁ receptor, 670, S170, S181
 Dopamine D₄ receptor gene, 3
 Dopamine D₂ receptors, 589
 Dopamine receptors, 101
 Dorsal raphe nucleus, 622, 710
 DRD3, 17
 DRD4, 3
 Drug abuse, 3, 650, 773
 Drug discontinuation, 258
 Drug discrimination, 119
 α -2-drug-effects, 495
 Drug interactions, 530
 Drug self-administration, 435, 575

E

Early genes, 93
 Eating disorders, 503
 EEG, 51
 Efficacy, 82S
 Electroconvulsive shocks, 91S
 Electroconvulsive therapy, 285, 391
 Electrophysiology, 622, 650
 Emission computed tomography, 368
 Emotional Memory, 312
 ERPs, 380
 Escape deficit, 247
 Evoked potentials, 51
 Evolution, 33S
 Excitatory postsynaptic potentials, 16S, S122
 Extrapyramidal side effects, 17

F

Firing pattern, 650
 Fluorocleopride, 589
 Fluoxetine, 247, 258, 435
 Flupenthixol, 575
 Follicular, 294
 Fos, 93
 Freezing, 731
 Frontal cortex, 268, 745, S143
 Functional brain imaging, 99S

G

G Protein, 650
 GABA_B, 650
 GABA interneuron, 161
 Galanin, 507
 Gene expression, 211
 Genetic association, 17
 GHB (γ -hydroxybutyrate), 662

Glutamate, 203, S143, S158
 Glutamatergic, 16S, S122
 Glycine, 203
 Granule cell, 46S
 Growth factor, 679
 [³⁵S]-GTPγS, 61S
 Guanfacine-pharmacology, 49S
 Gyrus cinguli, 36S

H

Hallucinogen, 16S, 77S, S122
 Haloperidol, 93, 211, 542
 Hereditary diseases, 51
 Heroin, 57S
 Hidden platform, 414
 Hippocampus, 69, 137, 341, 414, 474, 773, 46S, 91S
 Hostility, 75S
 5-HT_{1B}, 61S
 5-HT_{2A}, 77S, S122, S134, S143
 5-HT_{2C}, 77S
 5-HT₇, 352
 5-HT₆ receptor, 68S
 5-HT_{1A} receptors, 710, 745, 28S
 5-HT_{2A} receptors, 16S
 5-HT uptake, 74S
 5HT_{1A} receptor, 46S
 5-HT_{1A} Agonist, 622
 Human brain, 372
 Human development, 641
 Human 5-HT_{1B} gene, 238
 Human model, S158
 Humans, 44S
 HVA, 503
 γ-Hydroxybutyrate, 650
 5-hydroxytryptamine, 24S
 Hypericum perforatum, 247
 Hypothalamus, 312, 74S

I

Ibogaine, 119
 Imaging, 229
 Imipramine, 247
 In situ hybridization, 662, 679
 Immunocytochemistry, 68S
 Intracerebral injections, 560
 Intrinsic activity, 61S, 82S
 Inverse agonist, 61S
 Isoflurane, 589

K

Kainate, 341
 Ketamine, 137, 589, S143

L

Lamotrigine, S143
 Learning, 731
 Light-sensitivity, 40S
 Limbic areas, 68S
 Limbic cortex, 137
 Lithium, 229, 530, 91S
 Locomotor activity, 550, 560
 Locus coeruleus, 16S
 Long term recovery, 503
 LSD, 16S, 82S
 Luteal, 294
 Luteinizing hormone, 203
 Ly354740, S143

M

M100907, S134, S143, S211
 Magnetic resonance spectroscopy, 542
 mCPP, 82S
 MDL 100907, S143, S211
 Medial prefrontal cortex, 399
 Melatonin, 40S, 76S
 Memory, 28S, 474, S170
 Men, 294
 Mesolimbic, 694
 Meta-analysis, 32S
 Methamphetamine, 427
 MHPG, 503
 Microdialysis, 391, 560
 Mitochondria, 372
 MK-801, 414
 Monkey, 589, 601
 Monoamines, 679
 Mood disorders, 530
 Mood stabilizer, 519
 Morphine, 550
 Motor activity, 9S
 Motor performance, 414
 MRI, 63
 Muscarinic, S189
 Muscarinic cholinergic, 731
 Muscle tone, 101

N

Nafadotride, 304
 Naloxone, 28S
 Naltrexone, 43S
 Negative symptom, S211
 Nerve firing, 28S
 Neurodevelopment, 82
 Neuroendocrine, 99S
 Neurogenesis, 46S
 Neuroleptic, 211
 Neuroleptics, 17, 372, 633
 Neuronal activity, 601, 9S
 Neuronal cilia, 68S
 Neuropeptide, 33S
 Neuroscience, 2S
 Neotensin, 304
 Neurotoxicity, 427
 Nicotine, 19S
 Nicotine dependence, 560
 Nicotine withdrawal, 19S
 NMDA, 211, 341, S143, S158
 NMDA receptor antagonists, 137
 NMDA receptors, 414
 Noradrenaline-pharmacology, 49S
 Noradrenergic receptors, 69
 Norepinephrine, 611
 Noribogaine, 119
 Novelty seeking, 3
 Nucleus accumbens, 161, 229, 304, 399, 560, 773

O

Obsessive-compulsive disorder (OCD), 683
 7-OH-DPAT, 304
 Olfaction, 32S
 Opioid antagonist, 57S
 Opioid peptides, 28S
 Opioid receptors, 43S
 κ-opioids, 119
 Orbitofrontal cortex, 683, 91S

P

P3, 380

Panic disorder, 48S
 Parasympathetic nervous system, S189
 Paroxetine, 683
 Persistent sodium current, 161
 Pharmacogenetics, 17
 Pharmacokinetics, 294
 Pharmacology, 530
 Pharmacotherapy, S143
 Phencyclidine, 28, 137, S158
 Phobia, 312
 Phosphoinositide, 77S
 Phosphorus metabolites, 542
 Phosphorylation, 77S
 Physical activity, 679
 Pindolol, 26S, 91S
 Pineal gland, 76S
 Placebo effect, 670
 Plasma concentration, 43S
 Platelet, 99S
 Plus-maze, 312, 507
 Polymorphisms, 238
 Positron emission tomography (PET), 589, 633, 683, 694, S181
 Posterior cingulate cortex, 137
 Postmortem, 69, 99S
 Prefrontal cortex, 69, 161, 391, 601, 611, S122, S170
 Preoptic region, 24S
 Prepulse inhibition, 28, S134
 Processing negativity, 380
 Progesterone, 513
 Prolactin, 513
 Psychological state, 147
 Pulsatility, 110

Q

Quadazocine, 57S

R

Raphe, 74S, 9S, 33S, 52S
 Raphe system, 24S
 Rat, 101, 119, 247, 427, S134
 Rat brain, 662
 Receptor binding, 17
 Receptor occupancy, 101
 Receptors, S122, S189
 α₂-receptors, 49S
 Regional differences, 45S
 Reinstatement, 43S
 Relapse, 43S
 Release, 28S
 REM, S189
 REM sleep, 45S, 72S
 Response, 82
 Review, 3, 32S, 33S
 Reward, 670
 Risk factor, 17
 RNA editing, 82S

S

SCH23390, 641
 SCH 23390, 670
 Schizophrenia, 28, 69, 82, 137, 161, 19S, 203, 211, 32S, 36S, 372, 542, 641, 717, S122, S134, S143, S170, S181, S189, S203
 SCN, 352
 Scopolamine, 723
 Selective attention, 381
 Selective 5-HT Reuptake inhibitor, 268
 Selective serotonin reuptake inhibitors, 74S
 Self-administration, 43S
 Sensorimotor, 28

Sensory processing, 414
Serotonin, 238, 341, 352, 391, 435, 710, 755,
2S, 9S, 16S, 28S, 52S, 77S, 99S, S134, S143,
S211
Serotonin receptor, 82S
Serotonin receptors, 530
Sex differences, 445
Shell, 773
Single-unit, 127
Skin conductance, 40
Sleep, 258, 765, 24S, S189
Sleep deprivation, 455
Slow wave sleep, 455
Slow-wave activity, 455
Smell, 325
SMIT, 519
SNAP-25, 717
Spatial learning, 414
Speedball, 575
Spindle frequency activity, 455
Startle, 28, S134
Stress, 40, 399, 435, 9S, 28S, 46S

Striatum, 304, 341, 399, 427, 633, 694
Subjective effects, 435
Substance-related disorders, 51
Substantia nigra, 127
Suicide, 238
Suppression, 408
Symptoms, negative, S189
Symptoms, positive, S189
Synthesis, 28S

T

Tardive dyskinesia, 17
Temporal lobe, 542
Theta, 731
Thranscranial magnetic stimulation, 391
Trait, 99S
Transcriptional modification, 82S
Treatment, 258
Tryptophan, 755
Tyrosine hydroxylase, 399

U

Ultrastructure, 33S

V

Ventral tegmental area, 127
Vermis, 63

W

WIN 55212-2, 773
Women, 294
Working memory, 601, 611

Y

Yohimbine, 601